How Lantheus Holdings, Inc. stacks up

LNTH · against 454 other Healthcare companies listed in US-listed

Growth

49/ 100

Below the middle of the pack.

Ranked #295 of 455 · scores higher than 35% of peers

Bars: peers in each 10-point band of the growth score

25 peers with a growth score of 40–49, including LNTH · Click a bar to see the companies

Why growth scores 49?

Weighted metrics compared with all Healthcare companies.

A mix: stronger 3-year revenue growth, but weaker revenue growth than most Healthcare peers.

slower revenue growth over the last year: weaker than 63% of peers. Revenue growth: 2.3% vs peer median 6.1%
Earnings per share growth is close to the peer norm. Earnings per share growth: 5.8% vs peer median 9.8%
faster revenue growth over three years: stronger than 66% of peers. 3-year revenue growth: 11.4% vs peer median 5.8%

Metric by metric

Position: dot = LNTH, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.

Metric	LNTH	Peer median	Better than	Weight
Revenue growthHigher is better · 475 reported	2.3%	11.0%	27%	33%
Earnings per share growthHigher is better · 171 reported	5.8%	21.2%	34%	33%
3-year revenue growthHigher is better · 433 reported	11.4%	11.0%	52%	33%

Ranking by growth score

Top 5 and the companies ranked around LNTH

Rank	Company	Market cap	Growth	Overall
1	Phathom Pharmaceuticals, Inc.PHAT · US-listed	411M USD	100	53
2	AnaptysBio, Inc.ANAB · US-listed	1.4B USD	99	73
2	CorMedix Inc.CRMD · US-listed	408M USD	99	81
2	ImmunityBio, Inc.IBRX · US-listed	8.5B USD	99	31
2	Insight Molecular Diagnostics Inc.IMDX · US-listed	81M USD	99	27
⋯
289	Ocugen, Inc.OCGN · US-listed	277M USD	50	15
289	Surgery Partners, Inc.SGRY · US-listed	3.0B USD	50

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score